logo-loader
viewSareum Holdings PLC

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're looking to complete investigational new drug-enabling work for at least one of its TYK2/JAK1 candidates by the end of the calendar year with a decision on an initial target to be made in the second half.

Quick facts: Sareum Holdings PLC

Price: 0.8 GBX

AIM:SAR
Market: AIM
Market Cap: £26.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 slides as US/China tensions escalate

Headlines from the Proactive UK newsroom. The FTSE 100 slumped as China shut a US consulate in Chengdu in retaliation to a similar measure in Houston. The blue chip index fell 110 to 6,101. UK retail sales bounced 13.9% month-on-month June, following on from May’s 12.9% increase. Sales...

on 24/7/20

2 min read